Navigation Links
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Date:8/13/2009

ABBOTT PARK, Ill., Aug. 13 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the expansion of the company's XIENCE V(R) USA post-approval study designed to evaluate the safety and effectiveness of the company's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System in a real-world clinical setting out to five years. The expansion allows for more than 2,000 patients from the XIENCE V USA trial to be eligible to cross over into the landmark Dual Anti-Platelet Therapy (DAPT) Trial, an industry-wide collaboration with medical device and pharmaceutical companies.

"The expansion of the XIENCE V USA trial will enable Abbott to enroll more than 2,000 patients who may be eligible to also participate in the DAPT Trial to help advance the body of scientific knowledge regarding the best duration for patients to take blood-thinning medications after a stent procedure," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "We anticipate the DAPT Trial results will be instrumental in establishing definitive guidelines. As an industry leader, Abbott is proud to play a significant role in contributing patients to this important study."

The first patient was enrolled into the XIENCE V USA expansion by James Hermiller, M.D., director, Cardiac Catheterization Labs, The Care Group at St. Vincent Hospital in Indianapolis, Ind. Dr. Hermiller is a principal investigator of the XIENCE V USA trial along with Mitch Krucoff, M.D., FACC, FCCP, director, Cardiovascular Devices Unit, Duke Clinical Research Institute in Durham, N.C.

The XIENCE V USA trial expansion allows for an additional 3,000 patients to be enrolled into Abbott's study, which was originally designed to study 5,
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Abbott HIV Test Demonstrates Earlier Disease Detection
2. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
3. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
4. Abbott Named One of the Top 10 Companies for Scientists
5. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
6. Abbott to Present at Barclays Global Healthcare Conference
7. Abbott Employee Giving Sets New Records for Employee Participation and Total Donations
8. Abbott Announces 11 Percent Increase in Quarterly Dividend
9. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
10. Abbott Announces Earnings Guidance for 2009
11. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015  The University of California, San Diego,s ... UC San Diego Extension announced their third annual ...  12 – 14, 2015, at UC San Diego ... an intense exposure to best practices and the ... to biologists, process engineers and business executives planning ...
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter Alloys ... a revolutionary new archwire that allows orthodontists to simultaneously apply different forces to ... efficacy of SmartArch. “We’re thrilled about taking SmartArch one step closer to commercial ...
(Date:6/29/2015)... ... ... The global microfluidics market is expected to grow at ... The market is mainly driven by the rising geriatric population, growing Asian healthcare ... adequate healthcare and research infrastructure in emerging markets, dearth of skilled professionals in ...
(Date:6/29/2015)... According to a new market research report "Aptamers ... R&D), by Technology (SELEX, Other Technologies), by End Users (Academic ... to 2020", published by MarketsandMarkets, the global Aptamers Market is ... in 2015, at a CAGR of 17.89%. ... F igures spread through 125 P ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4
... First Ophthalmic Steroid Indicated for Inflammation and Pain, ... Inc., a,privately held ophthalmic-focused biopharmaceutical company, announced,today that ... approved its new,drug application for Durezol(TM) (difluprednate ophthalmic ... postoperative ocular inflammation,and pain. The approval came after ...
... FALLS, Ohio, June 24 Knowledge Enterprises,Inc. announced ... 4th Annual Orthopaedic Manufacturing & Technology Exposition and,Conference ... with total attendance,nearing 1,000. "Based on the initial ... to report that OMTEC has secured a permanent ...
... CAMBRIDGE, Mass., June 24 Tolerx, Inc., a,biopharmaceutical ... novel,therapies for the treatment of immune-mediated diseases, announced ... FierceBiotech "Fierce 15" list,designating it as one of ... of,FierceBiotech evaluated hundreds of privately-held firms based on ...
Cached Biology Technology:Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain 2Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain 3OMTEC 2008 Boasts Record Attendance and Secures Premier Position as Must-attend for Orthopaedic Companies 2Tolerx Named as One of the 'Fierce 15' Biotech Companies of 2008 2Tolerx Named as One of the 'Fierce 15' Biotech Companies of 2008 3
(Date:6/17/2015)... Maryland , June 17, 2015 ... mit DNA-Tests verbessert den Analyseprozess und senkt Laborkosten    ... Prime Standard: QIA) hat heute in den ... ® für die forensische Analyse ... zur Erstellung genetischer Fingerabdrücke bieten eine integrierte Lösung für ...
(Date:6/17/2015)... 17, 2015  Crossmatch™, a leading provider of ... U.are.U ® 4500 fingerprint readers have been ... Inc., a San Jose, CA ... security, improve accountability and reduce fraud at the ... identity confirmation for employee sign in and transaction ...
(Date:6/16/2015)... -- Fingerprint Cards has received an order of ... portfolio from one of its module partners in ... during the third quarter 2015. The sensors will be used ... Jörgen Lantto, CEO of FPC, comments: " This order ... from smartphone OEMs in integrating touch fingerprint sensors in   ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2
... organisms that feed on each other in the world,s streams ... whether the waterways flood or run dry than the amount of ... report online in the Oct. 14 issue of the journal ... in river systems will be threatened by increased variability in water ...
... global energy demands is the use of Poplar, a ... the most out of Poplar plantations, varieties that are ... or higher yields, for exampleare desired. But do these ... populations of Poplar? In particular, is the genetic makeup ...
... Calif.) A potent drug derived from an evergreen tree ... deadliest form of breast cancer. According to the National Cancer ... U.S. this year. Scientists at UC Santa Barbara, in ... mechanism by which this drug kills cancer cells. The team ...
Cached Biology News:Yale scientist helps pinpoint threats to life in world's rivers 2The risks and benefits of using poplars for biofuels 2UCSB scientists discover inner workings of potent cancer drug 2
Request Info...
Bovine Serum Albumin Heat Shock Diagnostic Grade Powder...
... provides the premium quality siRNAs you need ... can be readily ordered online by providing ... by providing the sense and antisense siRNA ... Validated and Silencer Pre-designed ...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer ...
Biology Products: